Next Article in Journal
Minor Role of Mitochondrial Respiration for Fatty-Acid Induced Insulin Secretion
Previous Article in Journal
Emulsifying Activity and Stability of a Non-Toxic Bioemulsifier Synthesized by Microbacterium sp. MC3B-10
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(9), 18973-18988; doi:10.3390/ijms140918973

A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma

Department of Internal Medicine, The Affiliated Tumor Hospital, Harbin Medical University, Haping Road 150 of Nangang District, Harbin 150081, Heilongjiang, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 9 August 2013 / Revised: 26 August 2013 / Accepted: 5 September 2013 / Published: 13 September 2013
(This article belongs to the Section Biochemistry, Molecular Biology and Biophysics)
View Full-Text   |   Download PDF [270 KB, uploaded 19 June 2014]   |  

Abstract

Estrogen-related genes and the fat mass and obesity-associated (FTO) gene play a critical role in estrogen metabolism, and those polymorphisms are associated with a poor prognosis in breast cancer. However, little is known about the association between these polymorphisms and the efficacy of anastrozole. The aim was to investigate the impact of the genetic polymorphisms, CYP19A1, 17-β-HSD-1 and FTO, on the response to anastrozole in metastatic breast carcinoma (MBC) and to evaluate the impact of those polymorphisms on various clinicopathologic features. Two-hundred seventy-two women with hormone receptor-positive MBC treated with anastrozole were identified retrospectively. DNA was extracted from peripheral blood and genotyped for five variants in three candidate genes. Time to progression was improved in patients carrying the variant alleles of rs4646 when compared to patients with the wild-type allele (16.40 months versus 13.52 months; p = 0.049). The rs4646 variant alleles were significantly associated with longer overall survival (37.3 months versus 31.6 months; p = 0.007). This relationship was not observed with the rs10046, rs2830, rs9926298 and rs9939609 polymorphisms. The findings of this study indicate that rs4646 polymorphism in the CYP19A1 gene may serve as a prognostic maker of the response to anastrozole in patients with MBC who are treated with anastrozole.
Keywords: metastatic breast carcinoma; aromatase gene; anastrozole; prognosis; polymorphism metastatic breast carcinoma; aromatase gene; anastrozole; prognosis; polymorphism
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Liu, L.; Bai, Y.-X.; Zhou, J.-H.; Sun, X.-W.; Sui, H.; Zhang, W.-J.; Yuan, H.-H.; Xie, R.; Wei, X.-L.; Zhang, T.-T.; Huang, P.; Li, Y.-J.; Wang, J.-X.; Zhao, S.; Zhang, Q.-Y. A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma. Int. J. Mol. Sci. 2013, 14, 18973-18988.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top